Invex Therapeutics Profit Margin

Invex Therapeutics posts a profit margin of -798.7% as of June 2026. That compares with -562.04% in the prior-year period — down 42.1% year over year. That is below the Healthcare sector average of 19.13%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Invex Therapeutics's profit margin was -562.04%. The latest reading is -798.7% — a 42.1% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 19.13% is typical. Invex Therapeutics's -798.7% is lower that level. That is roughly 4274.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Invex Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -798.7% as of June 2026; use YoY and peer views to separate noise from signal.

Context for IXC.AX's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 19.13%), and (3) consistency with growth and profitability. This page covers the first two; Invex Therapeutics's other metric pages and overview cover the third.